Pharmaceutical

BioHarvest Sciences Inc. Announces Closing of Private Placement of Convertible Notes

This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.Vancouver,…

12 months ago

Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano

Vancouver, British Columbia--(Newsfile Corp. - July 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"…

12 months ago

Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

PARIS, FRANCE / ACCESSWIRE / July 18, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology…

12 months ago

Pressure BioSciences Announces UltraShear Nano-CBD Roll-Out Program Enters Rapid Expansion Phase of Distribution and Partnering

During Interview with "Cannabis Talks" (Cannabis and Hemp Insider), CEO Ric Schumacher Reveals Transition into Aggressive Growth Phase for Revolutionary…

12 months ago

Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.

Advancing Next-Generation Wearable Patient Engagement and Diagnostic Technology Designed to Enable More Efficient Detection of Eye DiseasesALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos…

12 months ago

Laxxon Medical and CU Innovations at Anschutz Medical Campus Announce Strategic Partnership

DENVER, CO / ACCESSWIRE / July 17, 2023 / Laxxon Medical, a leading 3D screen printing pharma-technology company, announced today…

12 months ago

Elektrofi Appoints Victoria Sluzky as Chief Technology Officer to Drive Innovation and Technical Excellence

BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Today Elektrofi, a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to…

12 months ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology…

12 months ago

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Figure 1 Acumen Pharmaceuticals, Inc. Figure 2 Acumen Pharmaceuticals, Inc.Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating…

12 months ago